Jump to content

Leo van de Putte

Add links
From Wikipedia, the free encyclopedia
Levinus Boudewijn Abraham "Leo" van de Putte
BornJanuary 29, 1941
Rotterdam, Netherlands
Alma materLeiden University
Known forResearch in chronic inflammatory diseases, Rheumatoid arthritis, TNF-blocking agents, Immunology
Scientific career
FieldsRheumatology, Internal Medicine
InstitutionsRadboud University Nijmegen, Leiden University Medical Centre

Levinus Boudewijn Abraham "Leo" van de Putte (born 29 January 1941) is a Dutch rheumatologist and clinical investigator who is an emeritus professor of internal medicine and rheumatology at the Radboud University Nijmegen. His research activities contributed to insights into the pathogenesis of arthritis, the development of new diagnostic tools, and targeted therapies for chronic inflammatory arthritis, including rheumatoid arthritis. Between 1977 and 2012, he was also active at the international level, including clinical studies as well as activities related to the organisation of rheumatology in Europe.

Education

[edit]

Van de Putte studied medicine at Leiden University, graduated as MD in 1967, and completed a PhD in nephrology ("Recurrent or persistent hematuria: sign of mesangial immune complex disease")[1] in 1974. He had a full training in internal medicine and rheumatology at the Leiden University Medical Centre (1967-1974). He also studied violin with violinist Nap de Klijn and at the Hague Royal Conservatory. As a violinist, he was a regular soloist with student orchestras.[2][3]

Career

[edit]

Van de Putte was a professor of internal medicine and rheumatology at Radboud University Nijmegen in the Netherlands (1977-2003) and department chair of rheumatology at the Radboud University Medical Centre (1977-2003)[4] and the Sint Maartens Kliniek in Nijmegen (1998-2002).[4] He was chairman of the medical council of the Royal Dutch Academy of Arts and Sciences, among others involved in the 1998 nation-wide quality-assessment of Dutch medical research.[5][6] From 1994 to 2012, he was president of the Bertine Koperberg Foundation, organising regular international meetings on scientific topics in rheumatology and autoimmunity.[7]

Van de Putte has also been active at the international level. He was one of the initiators of the European Workshop for Rheumatology Research, organizing annual meetings for predominantly young researchers in the field.[8] From 1995 to 1997, he served as president of the European League Against Rheumatism (EULAR).[9] From 1999 to 2008, he was chief editor of the scientific journal Annals of the Rheumatic Diseases, after it became the official EULAR journal.[10]

After the fall of the Berlin Wall in 1989, and at the invitation of the German Government, van de Putte was an international advisor for the reorganisation of former East German universities, including in Jena and Berlin.[11][12][13] In 2011, he was awarded the Great Cross of the Order of Merit of the Federal Republic of Germany for his contributions to the field of rheumatology.[14]

Research

[edit]

Van de Putte’s research activities at the Radboud University Medical Centre have focused on chronic inflammatory processes, particularly rheumatoid arthritis. His research group studied factors determining the expression and chronicity of joint inflammation, in particular the distinct role of individual structures of the synovial joint, including cartilage[15][16] and synovial lining cells.[17][18][19] Additional studies in experimental arthritis indicated extensive inflammatory changes not only in the joint capsule but also in periarticular tissues, including ligaments, bone, and muscles.[20] Furthermore, a relationship between the severity and duration of arthritis on the one hand, and irreversible destruction of bone and cartilage on the other, could be demonstrated.[21] [22]

Van de Putte also played a leading role in the early and seminal studies on the biological D2E7, one of the first TNF-blocking agents currently known as adalimumab.[23][24] [25] This TNF-blocking biologic agent has proven to be a successful treatment modality for a broad array of chronic inflammatory diseases, including rheumatoid arthritis.

In 1998, his clinical research group was involved in the introduction and implementation of the anti-cyclic citrullinated peptides (anti-CCP) test in rheumatology, currently an important diagnostic tool for rheumatoid arthritis. This test was developed by the group of Walther van Venrooij at the Department of Biochemistry, Radboud University Nijmegen.[26][27]

Honours and Awards

[edit]
  • Honorary Fellow of the Royal College of Physicians (FRCP) (1997)[4]
  • Honorary member of the European League Against Rheumatism (EULAR) (1998)[28]
  • Honorary member of the Dutch Society for Rheumatology (2000)[29]
  • Jan van Breemen medal (2000)[30]
  • Medal of Honour of the Swedish Society of Medicine (2000)[31]
  • Great Cross of the Order of Merit of the Federal Republic of Germany (2011)[32]
  • Franziskus Blondel medal of the city of Aachen (2002)[33]
  • Honorary member of the German Society for Rheumatology (2004)[34]
  • Master Award, American College of Rheumatology (2007)[35]
  • Meritorious Service Award, European League Against Rheumatism (2009)[36]
  • Knighted as Officer of the Order of Orange-Nassau (2011)[37]
  • Carol Nachman medal, city of Wiesbaden[38]

References

[edit]
  1. ^ Van de Putte, LB; de la Riviere, GB; van Breda Vriesman, PJ (1974-05-23). "Recurrent or persistent hematuria: sign of mesangial immune complex deposition". New England Journal of Medicine. 290 (21): 1165–1170. doi:10.1056/NEJM197405232902104. PMID 4596116.
  2. ^ "Nieuwe Rotterdamse Courant" (in Dutch). 30 May 1961.
  3. ^ "Nieuwe Rotterdamse Courant" (in Dutch). 14 February 1963.
  4. ^ a b c "Radboud Repository".
  5. ^ "Discipline Report on (Bio)medical and Health Sciences Research in the Netherlands 1998". 2 December 1995.
  6. ^ Medical Committee Royal Netherlands Academy of Arts and Sciences. Royal Netherlands Academy of Arts and Sciences. 1999. ISBN 90-6984-249-1.
  7. ^ Vossenaar, E; Robinson, W (2005-10-01). "Citrullination and auto-immune disease: 8th Bertine Koperberg meeting". Annals of the Rheumatic Diseases. 64 (10): 1513–1515. doi:10.1136/ard.2005.045716. PMC 1755249. PMID 16162904.
  8. ^ "European Workshop for Rheumatology Research".
  9. ^ "EULAR Presidents".
  10. ^ Kvien, TK; Van de Putte, LB (2006-01-01). "EULAR expects further development in 2006". Annals of the Rheumatic Diseases. 65 (1): 1. doi:10.1136/ard.2006.066654. PMC 1797967. PMID 16344490.
  11. ^ Genth, E (2005-04-01). "Prof. Dr. Leo B A van de Putte". Z Rheumatol. 64 (3): 203–206. doi:10.1007/s00393-005-0729-1. PMID 15868339.
  12. ^ Genth, E. (2005). "Z Rheumatol - PubMed". Zeitschrift für Rheumatologie. 64 (3): 203–206. doi:10.1007/s00393-005-0729-1. PMID 15868339.
  13. ^ "Wiesbaden Newsdesk".
  14. ^ "Personalia". NRC. 7 July 2001.
  15. ^ "Chronic arthritis: why the joint? Proceedings of the 6th Bertine Koperberg Conference, Nijmegen, The Netherlands, 28-30 April 1994". Scandinavian Journal of Rheumatology Supplement. 101: 1–220. 1995. PMID 7747110.
  16. ^ Van den Berg, WB; Van de Putte, LB (1984-11-01). "Electrical charge of the antigen determines intraarticular antigen handling and chronicity of arthritis in mice". Journal of Clinical Investigation. 74 (5): 1850–1859. doi:10.1172/JCI111604. PMC 425365. PMID 6501574.
  17. ^ van Lent, PL; Holthuysen, AE; van den Bersselaar, LA; van Rooijen, N; Joosten, LA; van de Loo, FA; van de Putte, LB; van den Berg, WB (September 1996). "Phagocytic lining cells determine local expression of inflammation in type II collagen-induced arthritis". Arthritis and Rheumatism. 39 (9): 1545–1555. doi:10.1002/art.1780390915. PMID 8814067.
  18. ^ Van Lent, PL; Holthuysen, AE; Van den Bersselaar, LA; Van de Putte, LB (1995). "Role of macrophage-like synovial lining cells in localization and expression of experimental arthritis". Scandinavian Journal of Rheumatology. 101: 83–89. doi:10.3109/03009749509100906. PMID 7747137.
  19. ^ Barrera, P; Blom, A; van Lent, PL; van Bloois, L; Beijnen, JH; van Rooijen, N; de Waal Malefijt, MC; van de Putte, LB; Storm, G; van den Berg, WB (September 2000). "Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis". Arthritis and Rheumatism. 43 (9): 1951–1959. doi:10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K. PMID 11014344.
  20. ^ Kruijsen, MW; Van den Berg, WB; Van de Putte, LB (1983-06-01). "Sequential alterations of periarticular structures in antigen-induced arthritis in mice". British Journal of Experimental Pathology. 64 (3): 298–305.
  21. ^ Kruijsen, MW; van den Berg, WB; van de Putte, LB (July 1985). "Influence of the severity and duration of murine antigen-induced arthritis on cartilage proteoglycan synthesis and chondrocyte death". Arthritis and Rheumatism. 28 (7): 813–819. doi:10.1002/art.1780280713. PMID 4015727.
  22. ^ Van der Heijde, DM; Van Riel, PL; Nuver-Zwart, IH; Van de Putte, LB (1990-03-03). "Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up". Lancet. 335 (8688): 539. doi:10.1016/0140-6736(90)90771-v. PMID 1968547.
  23. ^ Van de Putte, LB; Rau, R (2003-12-01). "Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week phase II study". Annals of the Rheumatic Diseases. 62 (12): 1168–1177. doi:10.1136/ard.2003.009563. PMC 1754401. PMID 14644854.
  24. ^ den Broeder, AA; Joosten, LA; Saxne, T; Heinegård, D; Fenner, H; Miltenburg, AM; Frasa, WL; van Tits, LJ; Buurman, WA; van Riel, PL; van de Putte, LB; Barrera, P (April 2002). "Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation". Annals of the Rheumatic Diseases. 61 (4): 311–318. doi:10.1136/ard.61.4.311. PMC 1754066. PMID 11874832.
  25. ^ van de Putte, LB; Atkins, C; Malaise, M; Sany, J; Russell, AS; van Riel, PL; Settas, L; Bijlsma, JW; Todesco, S; Dougados, M; Nash, P; Emery, P; Walter, N; Kaul, M; Fischkoff, S; Kupper, H (May 2004). "Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease-modifying antirheumatic drug treatment has failed". Annals of the Rheumatic Diseases. 63 (5): 508–516. doi:10.1136/ard.2003.013052. PMC 1755008. PMID 15082480.
  26. ^ Schellekens, GA; de Jong, BA; Van den Hoogen, FH; Van de Putte, LB; Van Venrooij, WJ (1998-01-01). "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies". Journal of Clinical Investigation. 101 (1): 273–281. doi:10.1172/JCI1316. PMC 508564. PMID 9421490.
  27. ^ Van Venrooij, WJ; Van de Putte, LB (2005-11-01). "Is assaying autoantibodies useful for diagnosing early rheumatoid arthritis?". Nature Clinical Practice Rheumatology. 1 (1): 4–5. doi:10.1038/ncprheum0018. PMID 16932618.
  28. ^ "EULAR Honorary Members".
  29. ^ "Honorary members, Dutch Society for Rheumatology".
  30. ^ "Honorary members, Dutch Society for Rheumatology".
  31. ^ "Swedish Society of Medicine". 29 December 2000.
  32. ^ "Personalia". NRC. 7 July 2001.
  33. ^ "Franziskus Blondel Medal".
  34. ^ "Honorary members, German Society for Rheumatology".
  35. ^ "ACR Master Awardees" (PDF).
  36. ^ "EULAR Meritorious Service Award".
  37. ^ "Official Dutch Gazette". 14 December 2011.
  38. ^ "Carol Nachman medal".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Leo_van_de_Putte&oldid=1262810191"